A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether overall survival for the trabectedin group
is superior to the dacarbazine group for patients with advanced L-sarcoma (liposarcoma or
leiomyosarcoma).